阿替普酶静脉溶栓治疗急性脑梗死后脑出血转化的相关因素分析被引量：24

An analysis on factors related to hemorrhage transformation after intravenous alteplase thrombolysis in patients with acute cerebral infarction

原文传递

导出

摘要目的分析阿替普酶静脉溶栓治疗急性脑梗死(ACI)后发生出血转化的相关因素。方法回顾分析阿替普酶治疗ACI患者55例临床资料,分析溶栓治疗后出血转化的相关因素。结果 55例ACI患者中,9例(16.4%)发生出血转化;其中,症状性出血2例(3.6%)。入院时美国国立卫生研究院卒中量表(NIHSS)评分高、合并房颤和高血糖与溶栓后出血转化密切相关(P<0.05)。结论在ACI患者采用阿替普酶治疗的患者,入院时的NIHSS评分高、合并房颤和高血糖是溶栓后出血转化的预测因素。 Objective To analyze the factors related to hemorrhagic transformation after intravenous alteplase thrombolysis in the patients with acute cerebral infarction（ACI） .Methods Data of 55 patients with ACI underwent alteplase thrombolysis were retrospectively analyzed .The factors related to hemorrhagic transformation after alteplase thrombolysis were analyzed .Results Of 55 patients ,the hemorrhagic transformation occurred in 9 cases （16.4% ） ,of whom two cases （3.6% ） were with symptomatic hemorrhage .The high National Institutes of Health Stroke Scale （NIHSS ） score ,atrial fibrillation and hyperglycemia on admission were the factors closely related with the hemorrhagic transformation after thrombolytic therapy （P〈0 .05） .Conclusion High NIHSS score , atrial fibrillation and hyperglycemia on admission are the independent factors to predict the hemorrhagic transformation after alteplase thrombolytic therapy in ACI patients .

作者许燕平孙亚鸣刘春风

机构地区张家港市第一人民医院神经内科张家港市中医院神经内科苏州大学附属第二医院

出处《江苏医药》 CAS 2015年第19期2297-2300,共4页 Jiangsu Medical Journal

关键词急性脑梗死阿替普酶溶栓 Acute cerebral infarction Alteplase Thrombolysis

分类号 R741 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献15

1The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therpy for ischemic stroke [J]. Stroke, 1997,28(11):2109-2118.
2Larrue V, von Kummer R, Mtiller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plaminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study(ECASSII) [J]. Stroke, 2001,32 (2) : 438-441.
3Advani R, Naess H,Kurz MW. Evaluation of the implementa- tion of a rapid response treatment protocol for patients with acute onset stroke: can we increase the number of patients treated and shorten the time needed [J]? Cerebrovasc Dis Extra,2014,4(2) : 115-121.
4The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med, 1995,333 (24) : 1581-1587.
5Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4. 5 hours after ischemic stroke[J]. N Engl J Med,2008,359(13) : 1317-1329.
6Li Nl,Worthmann H, Heeren M, et al. Temporal pattern of cytotoxic edema in the perohematomal region after intracere- bral hemorrhage: a serial magnetic resonance imaging study [J] . Stroke,2013,44(4) : 1144-1146.
7Wu H, Wu T, Xu X, et al. Iron toxicity in mice collagenase- induced intracerebral hemorrhage[J]. J Cereb Blood Flow Metab, 2011,31 (5) : 1243-1250.
8Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt PA Stroke Survey[J]. Circulation, 2002,105(14): 1679-1685.
9Pundik S, McWilliams Dunnigan L, Blackham KL, et al. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-artial thrombolysis for acute stroke [J]. J Stroke Cerebrovasc Dis, 2008,17(5) :266-272.
10Zhang JB, Ding ZY, Yang Y, et al. Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrilla- tion[J]. Neurol Res, 2010,32 (4) : 353-358.